BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10507318)

  • 1. Variable expression of the folylpolyglutamate synthetase gene at the level of mRNA transcription in human leukemia cell lines sensitive, or made resistant, to various antifolate drugs.
    Takemura Y; Kobayashi H; Miyachi H
    Anticancer Drugs; 1999 Aug; 10(7):677-83. PubMed ID: 10507318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological activity and intracellular metabolism of ZD1694 in human leukemia cell lines with different resistance mechanisms to antifolate drugs.
    Takemura Y; Kobayashi H; Miyachi H; Gibson W; Kimbell R; Jackman AL
    Jpn J Cancer Res; 1996 Jul; 87(7):773-80. PubMed ID: 8698629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in cultured human leukaemia cells.
    Takemura Y; Kobayashi H; Gibson W; Kimbell R; Miyachi H; Jackman AL
    Int J Cancer; 1996 Mar; 66(1):29-36. PubMed ID: 8608962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.
    Liani E; Rothem L; Bunni MA; Smith CA; Jansen G; Assaraf YG
    Int J Cancer; 2003 Feb; 103(5):587-99. PubMed ID: 12494465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxicity of trimetrexate against antifolate-resistant human T-cell leukemia cell lines developed in oxidized or reduced folate.
    Miyachi H; Takemura Y; Kobayashi H; Ando Y
    Jpn J Cancer Res; 1997 Sep; 88(9):900-6. PubMed ID: 9369939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variable expression of RFC1 in human leukemia cell lines resistant to antifolates.
    Kobayashi H; Takemura Y; Ohnuma T
    Cancer Lett; 1998 Feb; 124(2):135-42. PubMed ID: 9500202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folylpolyglutamate synthetase expression in antifolate-sensitive and -resistant human cell lines.
    McGuire JJ; Russell CA
    Oncol Res; 1998; 10(4):193-200. PubMed ID: 9778690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of variant dihydrofolate reductase with decreased binding affinity to antifolates in MOLT-3 human leukemia cell lines resistant to trimetrexate.
    Miyachi H; Takemura Y; Kobayashi H; Ando Y
    Cancer Lett; 1995 Jan; 88(1):93-9. PubMed ID: 7850779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular pharmacokinetics of ZD1694 in cultured human leukaemia cells sensitive, or made resistant, to this drug.
    Takemura Y; Gibson W; Kimbell R; Kobayashi H; Miyachi H; Jackman AL
    J Cancer Res Clin Oncol; 1996; 122(2):109-17. PubMed ID: 8576277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line.
    Wang Y; Zhao R; Goldman ID
    Biochem Pharmacol; 2003 Apr; 65(7):1163-70. PubMed ID: 12663051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different antifolate-resistant L1210 cell variants with either increased or decreased folylpolyglutamate synthetase gene expression at the level of mRNA transcription.
    Roy K; Mitsugi K; Sirlin S; Shane B; Sirotnak FM
    J Biol Chem; 1995 Nov; 270(45):26918-22. PubMed ID: 7592937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential alterations of dihydrofolate reductase gene in human leukemia cell lines made resistant to various folate analogues.
    Miyachi H; Takemura Y; Kobayashi H; Ando K; Ando Y
    Jpn J Cancer Res; 1993 Jan; 84(1):9-12. PubMed ID: 8449831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia.
    Stark M; Wichman C; Avivi I; Assaraf YG
    Blood; 2009 Apr; 113(18):4362-9. PubMed ID: 19131550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular and molecular mechanisms of resistance to antifolate drugs: new analogues and approaches to overcome the resistance.
    Takemura Y; Kobayashi H; Miyachi H
    Int J Hematol; 1997 Dec; 66(4):459-77. PubMed ID: 9479873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-resistance studies of folylpolyglutamate synthetase-deficient, methotrexate-resistant CCRF-CEM human leukemia sublines.
    McGuire JJ; Heitzman KJ; Haile WH; Russell CA; McCloskey DE; Piper JR
    Leukemia; 1993 Dec; 7(12):1996-2003. PubMed ID: 8255099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
    Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
    Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate.
    Takemura Y; Ohnuma T
    Mt Sinai J Med; 1992 Oct; 59(5):419-24. PubMed ID: 1435841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of human acute leukemia cell line resistant to ZD9331, a non-polyglutamatable thymidylate synthase inhibitor.
    Kobayashi H; Takemura Y; Miyachi H
    Cancer Chemother Pharmacol; 1998; 42(2):105-10. PubMed ID: 9654109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
    Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
    Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.